Long-Acting Lenacapavir and Cabotegravir and Viral Suppression Among People With HIV

This case series examines viral suppression outcomes among patients with HIV with prior adherence challenges, treatment experience, and resistance initiating lenacapavir and cabotegravir.

Corresponding Author: Monica Gandhi, MD, MPH, Division of HIV, ID, and Global Medicine, University of California, San Francisco, 995 Potrero Ave, 4th Floor, Room 423D, San Francisco, CA 94110 (monica.gandhi@ucsf.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.